EUVIMEDEUVIMED entdecken
Crossref

Adipose Tissue-Derived Stromal/Stem Cells Transplantation with Cholecalciferol Supplementation in Recent-Onset Type 1 Diabetes Patients: Twelve Months Follow-Up

Joana R Dantas, Debora Batista Araujo, Karina Ribeiro Silva, Debora Lopes Souto, Maria de Fatima Carvalho Pereira, Luiz Ronir Raggio, Cesar Claudio-da Silva, Carlos Eduardo Couri, Angelo Maiolino, Carmen Lucia Kuniyoshi Rebellato, Debora Regina Daga, Alexandra Cristina Senegaglia und 5 weitere

Hormone and Metabolic Research · 01.08.2023 · 55 (08) · 536-545

DOI: 10.1055/a-2094-1039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.08.2023. Verfasst von Joana R Dantas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Nutrology and Diabetes Department, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate safety and therapeutic effect along 12 months of allogenic adipose tissue-derived stromal/stem cells (ASCs) transplantation with cholecalciferol (VITD) in patients with recent-onset type 1 diabetes (T1D). Prospective, phase II, open trial, pilot study in which patients with recent onset T1D received ASCs (1xKgx106 cells) and VITD 2000UI/day for 12 months (group 1) and were compared to controls with standard insulin therapy (group 2). Adverse events, C-peptide area under the curve (CPAUC), insulin dose, HbA1c and frequency of FoxP3+ in CD4+ or CD8+ T-cells(flow cytometry) were evaluated at baseline(T0), after 3(T3), 6(T6) and 12 months(T12). Eleven patients completed follow up (7:group 1;4:group 2). Group 1 had lower insulin requirement at T3(0.24±0.18vs0.53±0.23UI/kg,p=0.04), T6(0.24±0.15vs0.66±0.33 UI/kg,p=0.04) and T12(0.39±0.15vs0.74±0.29 UI/Kg,p=0.04).HbA1c was lower at T6 (50.57±8.56vs72.25±10.34 mmol/mol,p=0.01), without differences at T12 (57.14±11.98 in group 1 vs. 73.5±14.57 mmol/min in group 2, p=0.16). CPAUC was not significantly different between groups at T0(p=0.07), higher in group 1 at T3(p=0.04) and T6(p=0.006), but similar at T12(p=0.23). IDAA1c was significantly lower in group 1 than group 2 at T3,T6 and T12 (p=0.006, 0.006 and 0.042, respectively). IDDA1c was inversely correlated to FoxP3 expression in CD4 and CD8+ T cells at T6 (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1HumansCholecalciferolGlycated HemoglobinPilot ProjectsProspective StudiesFollow-Up StudiesInsulinAdipose TissueDietary SupplementsStem CellsForkhead Transcription Factors

Substanzen

CholecalciferolGlycated HemoglobinInsulinForkhead Transcription Factors

Autor:innen und Institutionen

  • Nutrology and Diabetes Department, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Laboratory of Tissue Bioengineering, Instituto Nacional de Metrologia Qualidade e Tecnologia Campus de Xerem, Duque de Caxias, Brazil.
  • Histology and Embryology Departament, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Institute of Public Health Studies, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Plastic Surgery, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Internal Medicine, Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto, Ribeirao Preto, Brazil.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

Dantas, J. R., Araujo, D. B., Silva, K. R., Souto, D. L., Pereira, M. F. C., Raggio, L. R., Claudio-da Silva, C., Couri, C. E., Maiolino, A., Rebellato, C. L. K., Daga, D. R., Senegaglia, A. C., Brofman, P. R. S., Baptista, L. S., Oliveira, J. E. P., Zajdenverg, L., & Rodacki, M. (2023). Adipose Tissue-Derived Stromal/Stem Cells Transplantation with Cholecalciferol Supplementation in Recent-Onset Type 1 Diabetes Patients: Twelve Months Follow-Up. Hormone and Metabolic Research, 55(08), 536-545. https://doi.org/10.1055/a-2094-1039

Vancouver

Dantas JR, Araujo DB, Silva KR, Souto DL, Pereira MFC, Raggio LR, et al. Adipose Tissue-Derived Stromal/Stem Cells Transplantation with Cholecalciferol Supplementation in Recent-Onset Type 1 Diabetes Patients: Twelve Months Follow-Up. Hormone and Metabolic Research. 2023;55(08):536-545. doi:10.1055/a-2094-1039

BibTeX
@article{Dantas2023,
  author = {Dantas, Joana R and Araujo, Debora Batista and Silva, Karina Ribeiro and Souto, Debora Lopes and Pereira, Maria de Fatima Carvalho and Raggio, Luiz Ronir and Claudio-da Silva, Cesar and Couri, Carlos Eduardo and Maiolino, Angelo and Rebellato, Carmen Lucia Kuniyoshi and Daga, Debora Regina and Senegaglia, Alexandra Cristina and Brofman, Paulo Roberto Slud and Baptista, Leandra S and Oliveira, Jose Egidio Paulo de and Zajdenverg, Lenita and Rodacki, Melanie},
  title = {Adipose Tissue-Derived Stromal/Stem Cells Transplantation with Cholecalciferol Supplementation in Recent-Onset Type 1 Diabetes Patients: Twelve Months Follow-Up},
  journal = {Hormone and Metabolic Research},
  year = {2023},
  volume = {55},
  number = {08},
  pages = {536--545},
  doi = {10.1055/a-2094-1039}
}
Kostenlos starten →